TABLE 1.
Characteristics of the Derivation Cohort of Patients With Quiescent CD or UC, Stratified by Clinical Relapse Over a 2-Year Follow-Up
| Characteristic | Relapse (n = 10) | Remission (n = 67) | P |
|---|---|---|---|
| Age (y), mean (SD) | 30.4 ± 8.8 | 38.7 ± 15.0 | 0.092 |
| Female, n (%) | 6 (60.0) | 29 (43.3) | 0.322 |
| Smoking history, n (%) | 0.654 | ||
| Never | 9 (90.0) | 52 (77.6) | |
| Former | 1 (10.0) | 14 (20.9) | |
| Current | 0 (0) | 1 (1.5) | |
| BMI (kg/m2), mean (SD) | 24.1 ± 4.0 | 26.1 ± 4.7 | 0.200 |
| IBD type | 0.245 | ||
| CD, n (%) | 5 (50.0) | 46 (68.7) | |
| UC, n (%) | 5 (50.0) | 21 (31.3) | |
| Disease duration (y), mean (SD) | 11.6 ± 6.3 | 11.8 ± 9.6 | 0.944 |
| Disease location (Montreal classification) | |||
| CD location | 0.651 | ||
| L1, n (%) | 1 (20.0) | 12 (26.0) | |
| L2, n (%) | 0 (0.0) | 9 (19.6) | |
| L3, n (%) | 4 (80.0) | 25 (54.3) | |
| UC extent | 0.672 | ||
| E1, n (%) | 0 (0.0) | 2 (9.0) | |
| E2, n (%) | 1 (20.0) | 3 (13.6) | |
| E3, n (%) | 4 (80.0) | 14 (63.6) | |
| Perianal disease (among patients with CD), n (%) | 1 (10.0) | 13 (19.4) | 0.472 |
| Laboratory results, mean (SD) | |||
| CRP (mg/L) | 2.3 ± 3.6 | 1.9 ± 2.3 | 0.697 |
| ESR (mm/h) | 7 ± 6.7 | 9 ± 6.7 | 0.430 |
| Fecal calprotectin (µg/g) | 72.2 ± 38.3 | 37.0 ± 41.6 | 0.252 |
| Interval between colonoscopy and study enrollment (d), mean (SD) | 160 ± 124 | 166 ± 118 | 0.886 |
| Complete histologic remission on colonoscopy, n (%) | 6 (60.0) | 56 (84.9) | 0.059 |
| Clinical remission for at least 1 year, n (%) | 8 (80.0) | 51 (76.1) | 0.787 |
| Past medical history | |||
| Prior biologic therapy, n (%) | 3 (30.0) | 23 (34.3) | 0.787 |
| Prior surgery, n (%) | 3 (30.0) | 21 (31.34) | 0.932 |
| Current therapies | |||
| 5-aminosalicylic acid therapy, n (%) | 5 (50.0) | 13 (19.4) | 0.033 |
| Immunomodulator therapy, n (%) | 4 (40.0) | 23 (34.3) | 0.726 |
| Biologic therapy, n (%) | 5 (50.0) | 60 (89.6) | 0.001 |